Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults â¥50 years of age

Article ID	Journal	Published Year	Pages	File Type
10967417	Vaccine	2012	9 Pages	PDF

Abstract

âº ChimeriVax-WN02 is a live attenuated vaccine for protection against West Nile virus. âº We assessed the immunogenicity and safety of ChimeriVax-WN02 in subjects aged â¥50. âº Subjects were randomized in 3 groups to receive 1 dose of a different formulation. âº Seroconversion was achieved at day 28 by >92% of subjects in each of the groups. âº ChimeriVax-WN02 was well tolerated in subjects in all groups.

Keywords

pre-membrane Cmax USP WNV PRNT PRM GMT SAE AUC plaque reduction neutralization test United States Pharmacopeia Older adults Yellow fever maximum concentration SOC adverse event Serious adverse event area under the curve Geometric mean titer Adverse reaction West Nile virus Envelope Clinical trial System organ class